David Green, MD
Pulmonary Disease · Shreveport, LANPI 1902874704
Payments from drug & device makers
Across 948 payments — averaging $2147.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.3M
- AstraZeneca$281K
- Eli Lilly$267K
- GSK$134K
- Sanofi$71K
- Actelion Pharmaceuticals US, Inc.$2K
- plus $5K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 83 | $1,275,798 |
| AstraZeneca(2 entities) | 132 | $281,241 |
| Eli Lilly | 3 | $267,032 |
| GSK | 279 | $133,596 |
| Sanofi | 37 | $70,595 |
| Actelion Pharmaceuticals US, Inc. | 168 | $2,484 |
| Boehringer Ingelheim | 42 | $777 |
| Insmed, Inc. | 26 | $526 |
| Grifols USA, LLC | 19 | $455 |
| Merck | 19 | $421 |
| United Therapeutics Corporation | 16 | $354 |
| Shionogi Inc | 5 | $287 |
| Amgen | 10 | $280 |
| Paratek Pharmaceuticals, Inc. | 7 | $259 |
| Genentech USA, Inc. | 14 | $219 |
| Johnson & Johnson(2 entities) | 14 | $218 |
| Regeneron Healthcare Solutions, Inc. | 10 | $210 |
| La Jolla Pharmaceutical Company | 5 | $192 |
| Mylan Specialty L.p. | 10 | $189 |
| Mallinckrodt Hospital Products Inc. | 8 | $177 |
| Bayer | 9 | $173 |
| Advanced Respiratory, Inc | 10 | $167 |
| Gilead | 2 | $146 |
| Baxter Healthcare | 6 | $113 |
| Verona Pharma, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $67 |
| Novartis | 2 | $42 |
| Boston Scientific | 1 | $27 |
| Viatris Specialty LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
How this compares
$2,036,162 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Shreveport
- Afsana AsharafShreveport$118K
- Robert HolladayShreveport$71K
- Prathik KrishnanShreveport$34K
- Himanshu DesaiShreveport$23K
- Scott HowardShreveport$20K
- Richard KammShreveport$15K
- David ChambersShreveport$13K
- Ahmed ViraniShreveport$12K
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.